MedTrace Logo

Desmopressin for Bedwetting in Children With SCD

NCT04420585 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2024-05-07

Study results available
· View outcomes & findings →

Summary

This study assesses if using the medication desmopressin will decrease nightime bedwetting in children with sickle cell disease.

Conditions

  • Nocturnal Enuresis
  • Anemia, Sickle Cell

Interventions

DRUG

Desmopressin

Two desmopressin 0.2 mg tablets at bedtime for 14 days and monitoring if \<50 % improvement

Sponsors & Collaborators

  • Montefiore Medical Center

    lead OTHER

Principal Investigators

  • Kerry Morrone, MD · Montefiore Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
8 Years
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-07
Primary Completion
2023-06-12
Completion
2023-06-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04420585 on ClinicalTrials.gov